Cocrystal Pharma, Inc. (COCP): Price and Financial Metrics

Cocrystal Pharma, Inc. (COCP): $2.58

0.03 (+1.18%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add COCP to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#248 of 455

in industry

COCP Price/Volume Stats

Current price $2.58 52-week high $3.29
Prev. close $2.49 52-week low $1.33
Day low $2.58 Volume 126
Day high $2.58 Avg. volume 21,776
50-day MA $1.94 Dividend yield N/A
200-day MA $1.77 Market Cap 26.25M

COCP Stock Price Chart Interactive Chart >


Cocrystal Pharma, Inc. (COCP) Company Bio


Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.


COCP Latest News Stream


Event/Time News Detail
Loading, please wait...

COCP Latest Social Stream


Loading social stream, please wait...

View Full COCP Social Stream

Latest COCP News From Around the Web

Below are the latest news stories about COCRYSTAL PHARMA INC that investors may wish to consider to help them evaluate COCP as an investment opportunity.

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

BOTHELL, Wash., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A. This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, viral and clinical measurements of influenza A infection in subjects dos

Yahoo | December 6, 2023

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent broad-spectrum PB2 inhibitor CC-42344 against pandemic and seasonal influenza A strains at the World Vaccine Congress West Coast. Cocrystal has initiated a Phase 2a human challenge trial with oral CC-42344 in the UK in subjects infected with influenza A, and plans to begin a Phase 1 trial with inh

Yahoo | November 29, 2023

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive Officer, will present a Company overview at Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on Monday, December 4 at 1:30 p.m. Eastern time. The conference is being held December 3-5 at the College of Business Executive Education Building at Florida Atlantic University in Boca Raton,

Yahoo | November 27, 2023

COCP: Cocrystal Pharma reports 3rd quarter financial results and provides updates on clinical trials.

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT No revenues were reported in the 3rd quarter of 2023 Cocrystal Pharma’s (NASDAQ:COCP) as the company’s drug candidates are still in development stage and milestone payments from Merck have not been received. Research and development expenses for the quarter increased to $4.2 million compared to $3.9 million in the 3rdquarter of

Yahoo | November 14, 2023

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviralDosing expected to begin later this year in Phase 2a human challenge trial with oral CC-42344 for the treatment of pandemic and seasonal influenza APhase 1 trial with inhaled CC-42344 expected to begin in the first half of 2024 BOTHELL, Wash., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial re

Yahoo | November 13, 2023

Read More 'COCP' Stories Here

COCP Price Returns

1-mo 21.13%
3-mo 68.63%
6-mo 40.98%
1-year 1.57%
3-year -83.59%
5-year -89.86%
YTD 49.81%
2023 -11.68%
2022 -75.00%
2021 -52.21%
2020 174.47%
2019 -86.24%

Continue Researching COCP

Here are a few links from around the web to help you further your research on Cocrystal Pharma Inc's stock as an investment opportunity:

Cocrystal Pharma Inc (COCP) Stock Price | Nasdaq
Cocrystal Pharma Inc (COCP) Stock Quote, History and News - Yahoo Finance
Cocrystal Pharma Inc (COCP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!